The Hippo Signaling Pathway Regulates Corneal Endothelial Regeneration

This study identifies the Hippo signaling pathway as a conserved regulator of corneal endothelial regeneration, demonstrating that inhibiting this pathway to activate YAP promotes wound healing in both rodent and primate models, thereby offering a novel therapeutic target for treating corneal endothelial decompensation.

The Gist

The Big Problem: The Eye's "Glass" That Can't Fix Itself

Imagine your eye is like a high-definition camera. The cornea is the clear glass lens at the front. On the very back of this glass sits a single layer of tiny, hexagonal tiles called Corneal Endothelial Cells (CECs).

Think of these cells as a team of diligent janitors. Their job is to pump water out of the cornea to keep it clear and dry.

• In mice and rabbits: If you scratch the floor (damage the cornea), these janitors are like a well-trained crew. They immediately start multiplying, filling in the gaps, and the floor gets clean again.
• In humans (and monkeys): These janitors are retired. They don't multiply. If you damage the cornea, the tiles don't get replaced. Instead, the remaining tiles stretch out like a thin rubber band to cover the hole. Eventually, they give up, water builds up, the cornea turns cloudy (like a foggy window), and vision is lost. This is a leading cause of blindness, and currently, the only cure is a risky cornea transplant.

The Discovery: The "Off Switch" That Was Stuck

The scientists in this paper wanted to know: Why can mice fix their eyes, but humans can't?

They discovered a biological "traffic light" system inside the cells called the Hippo Pathway.

• The Analogy: Imagine the Hippo pathway is a security guard standing at the door of a factory.
  • When the guard is active (Hippo ON), he stops the workers (cells) from entering the factory floor to multiply. He keeps them in the waiting room.
  • When the guard is inactive (Hippo OFF), the workers are free to run onto the floor and start building new tiles.

The Finding:
In mice and rabbits, when their cornea gets hurt, the security guard (Hippo) gets fired or goes on break. The workers (YAP, the downstream effector) run onto the floor, multiply, and fix the damage.
In humans and monkeys, the security guard never leaves his post, even after an injury. The workers stay stuck in the waiting room, and no repairs happen.

The Experiment: Testing the Theory

The researchers tested this theory in three ways:

1. Stopping the Repair (The "Brake" Test):
   They took mice and rabbits and used a drug to force the security guard to stay on duty (inhibiting YAP).

   • Result: The mice and rabbits failed to heal their eyes. The damage stayed. This proved that the "guard leaving his post" is essential for healing.

2. Starting the Repair (The "Gas Pedal" Test):
   They used a special drug called XMU-MP-1. Think of this drug as a remote control that fires the security guard.

   • Result: When they put drops of this drug into the eyes of injured mice and rabbits, the workers ran onto the floor. The eyes healed faster, the swelling went down, and the corneas became clear again.

3. The Real-World Test (The Monkey Trial):
   Since monkeys are much closer to humans than mice are, this was the big test. They injured the corneas of monkeys and applied the XMU-MP-1 eye drops.

   • Result: It worked! The monkeys' eyes healed. The "janitors" multiplied, filled the gaps, and the corneas became clear. Even better, they followed up one monkey a year later, and the eye was still healthy. The short treatment kick-started a permanent repair.

The Solution: A New Kind of Eye Drop

The paper suggests that we don't necessarily need to replace the whole cornea (transplant) or grow new cells in a lab. Instead, we might be able to treat corneal blindness with eye drops.

• The Drug: XMU-MP-1 is a small molecule that can be put in a drop.
• The Action: It turns off the "Hippo" security guard, allowing the eye's own cells to wake up, multiply, and fix the damage.
• The Safety: They tested it on mice for a month and found no side effects (no weird growths, no pressure changes). It seems safe.

The Bottom Line

This study is like finding the ignition key for the human eye's self-repair engine.

For decades, we thought human corneal cells were just "dead ends" that couldn't regenerate. This paper shows they actually have the engine, but the key (the Hippo pathway) is stuck in the "off" position. By using a drug to turn that key, we might be able to cure corneal blindness without surgery, simply by telling the eye's own cells, "Okay, you can start working now."

It's a shift from replacing the broken part to teaching the body how to fix itself.

Technical Summary

1. Problem Statement

Corneal endothelial cells (CECs) are critical for maintaining corneal transparency and hydration. In humans and other primates, CECs have a limited capacity for regeneration; once their density drops below a critical threshold (~500 cells/mm²), it leads to corneal decompensation, edema, and blindness. Currently, the only treatment is corneal transplantation, which is limited by a global shortage of donor tissue. While some pharmaceutical interventions (like ROCK inhibitors) show promise, none are clinically approved for regenerating CECs. Furthermore, the molecular mechanisms governing the stark difference in regenerative capacity between species (e.g., rodents vs. primates) remain poorly understood.

2. Methodology

The study employed a multi-species approach to investigate the role of the Hippo signaling pathway in CEC regeneration, utilizing both in vitro and in vivo models:

• Animal Models:
  • Rabbits: Cryoinjury model (transcorneal freezing).
  • Mice: UV-induced CEC damage model and AAV-mediated Yap1 knockdown (using Tie1 promoter for endothelial specificity).
  • Non-Human Primates (Cynomolgus Monkeys): Cryoinjury model and ex vivo corneal scraping model.
• Cell Models: Primary cultures of rabbit, monkey, and human CECs (including the B4G12 human CEC line).
• Interventions:
  • Inhibition: Verteporfin (blocks YAP-TEAD interaction) and siRNA knockdown of Yap1.
  • Activation: XMU-MP-1 (a specific small-molecule inhibitor of MST1/2 kinases, which blocks the Hippo pathway and prevents YAP phosphorylation). Other inhibitors (TRULI, DMX-5804) were also tested.
• Assessment Techniques:
  • Molecular: Western blot (p-YAP, p-MST1/2, p-LATS1/2), qRT-PCR, and immunofluorescence (YAP localization, Ki67, EdU, ZO-1, Na+/K+-ATPase).
  • Functional/Structural: Slit-lamp microscopy, Anterior Segment OCT (for corneal thickness/edema), in vivo confocal microscopy (for cell morphology/density), Alizarin Red staining, and Trypan Blue staining.
  • Safety: Long-term (12-month) follow-up in monkeys and 4-week safety studies in mice to assess ocular toxicity, intraocular pressure, and retinal health.

3. Key Contributions

• Mechanistic Discovery: The study identifies the Hippo-YAP signaling axis as a conserved regulator of corneal endothelial regeneration. It demonstrates that CEC regeneration requires the inactivation of the Hippo pathway, leading to the dephosphorylation and nuclear translocation of the effector YAP.
• Cross-Species Validation: The research bridges the gap between species by showing that while primates naturally fail to activate this pathway sufficiently after injury, pharmacological intervention can restore this capability.
• Therapeutic Candidate: The study validates XMU-MP-1 as a potent, non-invasive therapeutic agent capable of inducing CEC proliferation and functional recovery in rodents and, crucially, in non-human primates.

4. Key Results

• Endogenous Regulation: In regenerative species (rabbits and mice), CEC injury triggers a rapid downregulation of Hippo pathway kinases (MST1/2, LATS1/2), resulting in decreased YAP phosphorylation and increased nuclear YAP accumulation (observed at day 7 post-injury).
• Inhibition of Regeneration:
  • Pharmacological inhibition of YAP (Verteporfin) or genetic knockdown of Yap1 significantly suppressed CEC proliferation (reduced EdU/Ki67) and delayed wound healing in both rabbits and mice.
  • Treated animals exhibited persistent corneal edema, opacity, and loss of endothelial cell density.
• Promotion of Regeneration (XMU-MP-1):
  • In Vitro: XMU-MP-1 treatment increased YAP nuclear translocation, upregulated cell cycle genes (E2F1, CCND1, etc.), and significantly enhanced proliferation in rabbit, human, and monkey CECs.
  • In Vivo (Rodents): Topical application of XMU-MP-1 accelerated wound closure, restored corneal transparency, reduced edema, and increased cell density in rabbit and mouse models.
  • In Vivo (Primates): In cynomolgus monkeys, XMU-MP-1 treatment restored CEC density to pre-injury levels and normalized cell morphology (hexagonal shape) and function (ZO-1 and Na+/K+-ATPase expression) within 3 weeks.
• Long-Term Efficacy and Safety:
  • A 12-month follow-up in a treated monkey showed that the regenerated endothelium remained stable, with clear corneas and organized cell layers, without further intervention.
  • Safety studies in mice showed no adverse effects on corneal epithelium, intraocular pressure, or retinal structure after 4 weeks of treatment.
• Mechanism of Action: The data suggests that injury creates a permissive microenvironment where a transient pulse of YAP activation drives proliferation. Once a continuous monolayer is restored, contact inhibition likely reactivates the Hippo pathway to halt proliferation, preventing overgrowth.

5. Significance

This study provides a transformative potential treatment for corneal endothelial decompensation, a leading cause of corneal blindness.

• Non-Invasive Therapy: It proposes a pharmacological, non-surgical alternative to corneal transplantation, addressing the global donor shortage.
• Overcoming Species Barriers: By demonstrating efficacy in non-human primates, the study bridges the translational gap between rodent models and human clinical application.
• Self-Limiting Mechanism: The findings suggest that the Hippo pathway acts as a built-in "brake," ensuring that regeneration stops once the tissue is repaired, thereby minimizing the risk of uncontrolled cell growth (tumorigenesis) associated with YAP activation.
• Future Outlook: The results strongly support the progression of XMU-MP-1 (or similar Hippo inhibitors) toward clinical trials for treating human corneal endothelial failure.